Endocrine Abstracts

Introduction: The availability of Hybrid Closed Loop (HCL) automation in diabetes is a fast emerging technology. This technology is not freely available in our centre but a small number of our patients are self-funding it. We analysed data from the current cohort of our patients using HCL (up to 31st December 2023), to assess improvements in glycaemic control and quality of life for the patients and their families.

Objectives: To assess quantitative improvements in glycaemic control and qualitative improvement in diabetes burden in our current patients using HCL.

Methods: We retrospectively collected clinical data prior to the patient commencing on HCL and at a minimum of 3 months post HCL treatment. Prospective patient/parent questionnaires have also been collated.

Results: 42 children and young people (12% of our clinic population) aged between 2 and 18 years were using HCL at the time of study. Results showed:

- a reduction in median HbA1c of 8 mmol/mol; - a reduction of median average glucose of 1.8 mmol/l; - an increase of median time in range of 22% - giving them over 5 hours more each day in target; - a reduction of median time in hypoglycaemia (0.75%) and time spent very high (9.1%). These improvements are noted across all age groups (pre-school; primary age and post-primary). There is also a huge improvement in perceived quality of life with a significant reduction in diabetes burden and this has been universal for all patients and their families.

Conclusions: HCL technology has made a remarkable improvement to both glycaemic control and quality of life in all our patients using this modality. This highlights the case for it be funded in our centre.